About this trial
Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.
Eligibility criteria
Qualifiers
All children diagnosed with CDD age 1-month to 100 years of age that are receiving care at one of the study institutions or are registered with the International CDKL5 Disorder Database will be considered for the study population.
Disqualifiers
Individuals who do not meet study inclusion criteria.
Trial design
Treatments tested in this trial
- No intervention.
Treatment groups
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
National Institutes of Health (NIH)
Collaborator
International Foundation for CDKL5 Research
Collaborator